-       Report 
- October 2025
-  192 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
          -       Report 
- October 2025
-  379 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- February 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
            -       Clinical Trials 
- April 2025
-  60 Pages 
- Global 
   From       €1431EUR$1,600USD£1,259GBP 
      €1789EUR$2,000USD£1,574GBP 
            -       Drug Pipelines 
- April 2025
-  60 Pages 
- Global 
   From       €1431EUR$1,600USD£1,259GBP 
      €1789EUR$2,000USD£1,574GBP 
             -       Clinical Trials 
- April 2025
-  60 Pages 
- Global 
   From       €894EUR$1,000USD£787GBP 
      €1118EUR$1,250USD£983GBP 
            -       Clinical Trials 
- April 2025
-  80 Pages 
- Global 
   From       €1431EUR$1,600USD£1,259GBP 
      €1789EUR$2,000USD£1,574GBP 
            -       Clinical Trials 
- April 2025
-  60 Pages 
- Global 
   From       €1431EUR$1,600USD£1,259GBP 
      €1789EUR$2,000USD£1,574GBP 
            -       Clinical Trials 
- April 2025
-  60 Pages 
- Global 
   From       €1431EUR$1,600USD£1,259GBP 
      €1789EUR$2,000USD£1,574GBP 
            -       Report 
- May 2024
-  137 Pages 
- Global 
   From       €4941EUR$5,524USD£4,346GBP 
      €5813EUR$6,499USD£5,113GBP 
            -       Report 
- January 2022
-  200 Pages 
- Global 
   From       €5367EUR$6,000USD£4,721GBP 
      €6708EUR$7,500USD£5,901GBP 
            -       Report 
- January 2022
-  60 Pages 
- Global 
   From       €2826EUR$3,160USD£2,486GBP 
      €3533EUR$3,950USD£3,108GBP 
            -       Report 
- January 2022
-  60 Pages 
- Global 
   From       €2826EUR$3,160USD£2,486GBP 
      €3533EUR$3,950USD£3,108GBP 
          -       Report 
- April 2023
-  120 Pages 
- Global 
   From       €4249EUR$4,750USD£3,737GBP 
            -       Report 
- May 2024
-  136 Pages 
- Global 
   From       €4941EUR$5,524USD£4,346GBP 
      €5813EUR$6,499USD£5,113GBP 
          -       Report 
- November 2023
-  178 Pages 
- Global 
   From       €4025EUR$4,500USD£3,541GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
       
      The Conjunctivitis Drug market is a subset of the Optical Disorders Drugs market, which includes drugs used to treat a variety of eye conditions. Conjunctivitis is an inflammation of the conjunctiva, the thin, transparent membrane that lines the inner surface of the eyelids and covers the white part of the eye. Conjunctivitis drugs are used to treat the symptoms of the condition, such as redness, itching, and discharge. These drugs can be administered topically, orally, or intravenously, depending    on the severity of the condition. Commonly prescribed drugs for conjunctivitis include antibiotics, antihistamines, and corticosteroids.
The Conjunctivitis Drug market is highly competitive, with a number of companies offering a variety of products. Some of the major players in the market include Allergan, Bausch + Lomb, Merck, Novartis, Pfizer, and Santen Pharmaceuticals. Show Less   Read more